{
    "id": "6402c3fd201352f04a000009",
    "question": "Was prehospital transdermal glyceryl trinitrate effective for stroke in the RIGHT-2 trial?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "To answer this question, I will go through the steps of evaluating the effectiveness of prehospital transdermal glyceryl trinitrate (GTN) for stroke treatment in the RIGHT-2 trial. **Step 1: Understanding the RIGHT-2 trial** The RIGHT-2 trial was a randomized, double-blind, placebo-controlled trial that investigated the efficacy and safety of prehospital transdermal glyceryl trinitrate (GTN) for acute ischemic stroke. **Step 2: Identifying the primary outcome** The primary outcome of the RIGHT-2 trial was the modified Rankin Scale (mRS) score at 6 months post-stroke. **Step 3: Analyzing the trial results** According to the published results of the RIGHT-2 trial, the prehospital administration of transdermal GTN did not significantly improve the outcome in patients with acute ischemic stroke. **Step 4: Drawing a conclusion** Based on the trial results, prehospital transdermal glyceryl trinitrate was not found to be effective in improving outcomes in patients with acute ischemic stroke. **Answer** {\"step_by_step_thinking\": \"The RIGHT-2 trial found that prehospital transdermal glyceryl trinitrate was not effective in improving outcomes in patients with acute ischemic stroke.\", \"answer_choice\": \"B\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 38.691288471221924
}